Page 11234..1020..»

Archive for the ‘Genetic Testing’ Category

Kelly Morgan, MS, CGC, on Genetic Testing Education Aiding in Disseminating Information – Cancer Network

The MSK expert explained that pre- and post-test educatin on genetic testing could help patients and providers alike to better understand the results.

Pre- and post-test education on genetic testing may help patients disseminate information more easily to their health care providers, according to Kelly Morgan, MS, CGC.

In a recent study, presented at the 2020 ASCO Virtual Scientific Program, the BRCA Founder OutReach (BFOR) offered pre-testing online education with posttest engagement of primary care providers, which appeared to be effective in educating both patients and providers alike.

So, in terms of the participant experience, we found satisfaction to be high both after this pre-test education and also after genetic testing. Knowledge was high after the pre-test education, which was very important from our perspective to make sure our participants were able to adequately receive the information they need to make a decision like this, said Morgan, a genetic counselor at Memorial Sloan Kettering Cancer Center.

In an interview with CancerNetwork, Morgan explained how these results can affect health care providers knowledge of genetic testing moving forward.

Transcription:

From our perspective, we really see this model as a way to more effectively disseminate information. So whether that be to patients but also importantly to their doctors. So you're absolutely right in terms of having a multidisciplinary team and the more that we can engage not only a patient, but their community and their providers to build the biggest sort of network of resources we can, I think that's important. And these digital tools I think, can create a centerpiece for patients and their physicians to come together and both learn

Read the rest here:
Kelly Morgan, MS, CGC, on Genetic Testing Education Aiding in Disseminating Information - Cancer Network

The Limitations and Promise of Genetic Testing in Psychiatry – Psych Congress Network

Genetic testing may be a helpful tool in diagnosing autism and intellectual disability, but published data does not adequately support its use as a standard predictor of antidepressant response, James B. Potash, MD, MPH, said during a session at the virtual 2020 Psych Congress Elevateconference on the role of genetic testing in psychiatry.

There is ample reason to think that genetic variation ought to predict antidepressant response but research has shown mixed results, said Dr. Potash, who is the Henry Phipps Professor, Director and Psychiatrist-in-Chief, at Johns Hopkins Medicine, Baltimore, Maryland, and has been working in the field of genetics of mood disorders for more than 20 years.

Dr. Potash is a member of the American Psychiatric Association Council on Research, which had a task force analyze the issue in recent years. In a systematic review of pharmacogenetic tests of antidepressants, the task force found that the quality of the data provided by the tests on pharmacodynamicshow a drug affects the brainwas low, he said. However, the study, published in The American Journal of Psychiatry, found the tests provided higher-quality data on regarding particular genes related to how a drug is metabolized in the liver.

Their conclusion was at present there are insufficient data to support the widespread use of combinatorial pharmacogenetic testing in clinical practice, although there are clinical situations in which the technology may be informative, particularly in predicting side effects, Dr. Potash explained.

Similarly, an International Society of Psychiatric Genetics committee on genetic testing last year reached the conclusion that evidence to support widespread use of pharmacogenetic tests is inconclusive. But the statement also says when pharmacogenetic testing results are already available, providers are encouraged to integrate this information into their medication selection and dosing decisions, he said.

As for the future direction of genetic testing in psychiatry, Dr. Potash said there is ongoing research into its use in bipolar disorder.

A study involving 2500 people with bipolar disorder, published in Lancet by the International Consortium on Lithium Genetics, found some genetic variations were statistically significantly associated with response to lithium treatment. People with the highest Polygenic Risk Score (PRS) for schizophrenia had the lowest response to lithium treatment, and people with the lowest schizophrenia PRS had the highest response to lithium treatment. In addition, a paper recently published in Molecular Psychiatry found that people with bipolar disorder who had the lowest PRS for depression were 75% more likely to respond favorably to lithium, compared with those with the highest depression PRS scores.

Dr. Potash also spoke about the importance of a more traditional genetic research tool: collecting a detailed family history from a patient.

It has been known for a long time but its not always implemented, he said, noting that familial recurrence risk has been analyzed for more than 100 years.

For example, he explained, if one parent has schizophrenia and no siblings or second-degree relatives do, a child has a 6% risk of developing schizophrenia. But if one parent, two siblings, and a second-degree have the disorder, the relative the risk of a child inheriting it is 36%.

That kind of information is important, he said. Very important. Its valuable.

Terri Airov

References

Amare AT, Schubert KO, Hou L.,et al.Association of polygenic score for major depression with response to lithium in patients with bipolar disorder.Molecular Psychiatry. 2020 March 16;[Epub ahead of print].

Genetic Testing Statement. International Society of Psychiatric Genetics. Accessed July 15, 2020.

Hou L, Heilbronner U, Degenhardt F, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016;387(10023):1085-1093.

The role of genetic testing in psychiatry. Presented at Psych Congress Elevate: Virtual; July 26, 2020.

Zeier Z, Carpenter LL, Kalin NH, et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. The American Journal of Psychiatry. 2018;175:873886.

View original post here:
The Limitations and Promise of Genetic Testing in Psychiatry - Psych Congress Network

Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center – DocWire News

This article was originally published here

J Gen Intern Med. 2020 Jul 27. doi: 10.1007/s11606-020-06064-x. Online ahead of print.

ABSTRACT

BACKGROUND: Prior studies suggest that referral to genetic counseling and completion of genetic testing vary by race/ethnicity; however, the data are limited.

OBJECTIVE: We sought to evaluate patterns of genetic testing and clinical outcomes across race/ethnicity at a hereditary breast and ovarian cancer center.

DESIGN: The medical records for all patients undergoing genetic assessment at a hereditary breast and ovarian cancer center were reviewed and stratified by self-reported race/ethnicity (non-Hispanic White, Hispanic, non-Hispanic Black, and Asian).

PARTICIPANTS: A total of 1666 patients met inclusion criteria (non-Hispanic Whites, 1367; Hispanics, 85, non-Hispanic Blacks, 101; Asians, 113).

MAIN MEASURES: Demographics, patient characteristics, and referral patterns for patients who underwent genetic testing were analyzed using Kruskal-Wallis tests, chi-square test, or Fishers exact tests, stratifying by self-reported race/ethnicity. Pathogenic mutations and variants of unknown significance (VUS) were reviewed. Outcomes of patients with genetic mutations and personal history of breast and/or gynecologic malignancies were compared.

KEY RESULTS: Non-Hispanic Whites were more likely to be referred due to family cancer history compared to all other ethnicities while Non-Hispanic Blacks, Hispanics, and Asians were more likely to be referred due to personal history of cancer (p < 0.001). Non-Hispanic Blacks and Hispanics were more likely to have advanced-stage cancer at the time of genetic testing (p < 0.02). Rates of mutations did not differ by race/ethnicity when Ashkenazi Jewish patients were excluded (p = 0.08). Among patients found to have a BRCA1/2 mutation, Non-Hispanic Whites were more likely to undergo cancer screening and risk-reducing surgery compared with all other ethnicities (p = 0.04).

CONCLUSIONS: Minority patients were more likely to utilize genetic services following a cancer diagnosis and less likely due to family cancer history, suggesting a missed opportunity for mutation detection and cancer prevention in this population. Efforts to eradicate racial/ethnic disparities in early access to genetic testing and guided cancer prevention strategies are essential.

PMID:32720237 | DOI:10.1007/s11606-020-06064-x

See the rest here:
Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center - DocWire News

At Home Genetic Testing Market: an Increase in Revenue That Will Change the Game After COVID 19: 23andMe, MyHeritage, LabCorp – Market Research Posts

The Global At Home Genetic Testing Market Research Report provides customers with a complete analytical study that provides all the details of key players such as company profile, product portfolio, capacity, price, cost, and revenue during the forecast period from 2020 to 2027. The report provides a full assessment. At Home Genetic Testing market with future trends, current growth factors, meticulous opinions, facts, historical data and statistically supported and industry-validated market data.

This At Home Genetic Testing market research provides a clear explanation of how this market will impress growth during the mentioned period. This study report scanned specific data for specific characteristics such as Type, Size, Application and End User. There are basic segments included in the segmentation analysis that are the result of SWOT analysis and PESTEL analysis.

To Learn More About This Report, Request a Sample Copy:https://www.worldwidemarketreports.com/sample/339093* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

23andMe, MyHeritage, LabCorp, Myriad Genetics, Ancestry.com, Quest Diagnostics, Gene By Gene, DNA Diagnostics Center, Invitae, IntelliGenetics, Ambry Genetics, Living DNA, EasyDNA, Pathway Genomics, Centrillion Technology, Xcode, Color Genomics, Anglia DNA Services, African Ancestry, Canadian DNA Services, DNA Family Check, Alpha Biolaboratories, Test Me DNA, 23 Mofang, Genetic Health, DNA Services of America, Shuwen Health Sciences, Mapmygenome, Full Genomes are some of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

Key players in the At Home Genetic Testing market were identified through a second survey, and their market share was determined through a primary and second survey. All measurement sharing, splitting, and analysis were solved using a secondary source and a validated primary source. The At Home Genetic Testing market report starts with a basic overview of the Industry Life Cycle, Definitions, Classifications, Applications, and Industry Chain Structure, and when used together, how key players can meet market coverage, offered characteristics, and customer needs It helps to understand.

The report also makes some important suggestions for new At Home Genetic Testing market projects before evaluating their feasibility. Overall, this report covers At Home Genetic Testing market Sales, Price, Sales, Gross Profit, Historical Growth,and Future Prospects. It provides facts related to the widespread merger, acquisition, partnership, and joint venture activities on the market.

This report includes market size estimates of value (million US $) and trading volume (K MT). The top-down and bottom-up approaches are used to estimate and validate the market size of the At Home Genetic Testing market, estimating the size of various other subordinate markets in the overall market. All ratio sharing, splitting, and analysis were determined using the secondary source and the identified primary source.

What At Home Genetic Testing Market report offers:

Remarkable Attributes of At Home Genetic Testing Market Report:

Share Your Precise Requirements: https://www.worldwidemarketreports.com/quiry/339093

Special Requirements?We value your investment and offer customization as per your requirements.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

See more here:
At Home Genetic Testing Market: an Increase in Revenue That Will Change the Game After COVID 19: 23andMe, MyHeritage, LabCorp - Market Research Posts

Genetic Studies Could Pave the Way to New Pain Treatments – Pain News Network

By Dr. Lynn Webster, PNN Columnist

Millions of Americans order DNA test kits to determine their ancestries. Knowing where you come from can be entertaining. However, DNA testing can also help identify your risk of developing some diseases, including chronic pain.

Prenatal testing for genetic disorders is common. But genetic testing is also increasingly used to determine the risk of developing certain diseases or potential responses to specific drugs.

Currently, little is known about how to use genes to make an individual more or less sensitive to pain, or to learn the likelihood that someone will respond in a particular way to an analgesic based on their genetics. The good news is that we are on the cusp of gaining more information about the genes that control pain and pain treatments, and that knowledge should allow us to develop targeted pain therapies.

Most physicians still believe that everyone experiences pain in the same way. Research recently published in Current Biology discovered a genethe so-called "Neanderthal gene"that is associated with increased sensitivity to pain. Recognizing that a mutation of a specific gene can influence pain perception may be illuminating for many members of the medical profession.

Pain specialists have known for a long time that given the same stimulus, some people feel more pain than others. The truth is, there are several genes besides the Neanderthal gene that determine how an individual experiences pain. Some genes increase our sensitivity to pain, while other genes decrease it. Some genes influence how pain is processed, while other genes determine an individual's response to an analgesic.

The ability for an analgesic to provide pain relief in an individual is partially determined by the genetics of the receptor to which the pain medication binds. These genes are different from pain-sensitivity genes. For example, oxycodone may be very effective in relieving pain for one individual, but only partially effective for another.

Optimal pain relief requires recognition that each individual responds uniquely to a given analgesic. Doctors are beginning to provide gene therapy for cancer patients. Advancements in research may someday allow us to do the same for patients with pain.

The array of pain responses to the same stimulus is a major reason why one-size-fits-all dosing of pain medications is flawed. A given dose may leave some patients undertreated and others over-treated. Unfortunately, regulators who set arbitrary dose limits fail to understand or consider this biologic variability.

Differing clinical responses to pain stimuli and medications underscore the need to individualize therapy. Knowing more about the biology of pain can help us to understand each individuals response to painful stimuli and the variable response to any therapy.

How we experience pain is a result of both environmental and genetic features. The genetic factors are what we inherit. Environmental factors which we develop rather than inherit include cultural attitudes, emotions, and individual responses to stress. Our personality and lifes experiences are included in the environmental factors that contribute to our experience of pain. Therefore, pain is a result of genetic and environmental interactions. Both can make an individual more or less sensitive to stimuli or analgesia. It is a complex and dynamic process.

The so-called Neanderthal gene is not a new discovery but was newly recognized in Neanderthals. The discovery is interesting, because it implies the gene has an evolutionary purpose. The gene is known as SCN9. There are several pain syndromes associated with the genetic mutations of the SCN9 gene, including some types of back pain and sciatica. Mutations of this gene can result in the total absence of pain or a heightened pain expression. The type of mutation determines the phenotype (or personal characteristics) of our response to a painful stimulus.

It is unclear how Neanderthals benefited biologically from increased pain sensitivity. As we know, acute pain elicits an alarm and is considered protective. It teaches us to avoid dangers that can threaten our life, and prevents us from walking on a broken leg until it heals sufficiently to bear our weight.

Evolution may not have been concerned about the effects of chronic pain. The Neanderthals' limited life expectancy, and the fact that their survival depended on strong physical conditioning, may have made chronic pain a non-issue. Chronic pain may have made survival difficult, or even impossible, for the Neanderthals.

The recent discovery that Neanderthals had the SCN9 gene should not be surprising, given the fact that modern humans shared a common ancestor with Neanderthals. The Neanderthal gene study is of particular interest to me, because I am working with several companies that are exploring potential drugs to affect the function of the SCN9 gene. The companies have different approaches, but they all are trying to find a way to dial down an individual's sensitivity to painful stimuli.

Since the SCN9 gene can be responsible for the total absence of all pain, as well as several extreme forms of pain, it may be reasonable to target the SCN9 gene to modulate pain.

My hope is that manipulation of the SCN9 gene will reduce pain sensitivity, making it easier to control pain by adjusting the dose and type of drug we prescribe.

It is possible one or more drugs that target the SCN9 gene will be available within the next 4-6 years. If that occurs, it could be game changer for people in pain. We can then thank our Neanderthal ancestors for the evolutionary gift.

Lynn R. Webster, MD, is a vice president of scientific affairs for PRA Health Sciences and consults with the pharmaceutical industry. He is author of the award-winning book, The Painful Truth, and co-producer of the documentary, It Hurts Until You Die. You can find Lynn on Twitter: @LynnRWebsterMD

Continue reading here:
Genetic Studies Could Pave the Way to New Pain Treatments - Pain News Network

Europe Genetic Testing Market 2020 | Research Objectives and Methodology, Growth Analysis, Top Manufacturers Sales, and Cost Structures Forecast 2024…

The Europe Genetic Testing Market report 2020 covers all the significant developments which are recently being adopted across the global market. The prime objective of the Europe Genetic Testing market report is to provides an in-depth analysis of all market dynamics including drivers and restraints, and trends, and opportunities. The Europe Genetic Testing market report covers both the demand and supply aspects of the market. The report also highlighted the future trends in the Europe Genetic Testing market that will impact the demand during the forecast period.

Scope of the Report:

As per the scope of this report, genetic testing is a test performed to identify the presence of a particular gene/s with a particular sequence of the genome. The gene/s can be identified either directly through sequencing or indirectly through various methods.

Get a Sample Copy of the Report https://www.industryresearch.co/enquiry/request-sample/13999555

Market Overview:

Some of the Top Key Players of Europe Genetic Testing Market Report Are:

Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999555

Key Market Trends:

Diagnostic testing is the segment under type of testing that is expected to grow fastest during the forecast period

Predictive and presymptomatic testing dominated the European genetic testing market system, as it is utilized for the detection of gene mutations related to disorders that appear after birth, frequently in later stages of life. Such tests can be of assistance to individuals having a family member with a genetic disorder, though they are free of any features of the disorder while testing.

Diagnostics testing is expected to register a CAGR of 14.29%, as it is used to diagnose or rule out a specific genetic condition. In most cases, genetic testing is used to confirm a diagnosis when a particular condition is suspected based on physical mutations and symptoms. Furthermore, companies, such as Centogene and NIMGenetics, offer a wide range of genetic diagnostic services in Europe, which is further accelerating the growth of the market.

The Report Covers:

Purchase this Report (Price 3850 USD for single user license) https://www.industryresearch.co/purchase/13999555

Detailed TOC of Europe Genetic Testing Market Report 2020-2024:

1 INTRODUCTION1.1 Study Deliverables1.2 Study Assumptions1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS4.1 Market Overview4.2 Market Drivers4.2.1 Increasing Emphasis on Early Disease Detection and Prevention4.2.2 Increasing Demand for Personalized Medicine4.2.3 Increasing Application of Genetic Testing in Oncology4.3 Market Restraints4.3.1 High Costs of Genetic Testing4.3.2 Social and Ethical Implications of Genetic Testing4.4 Porters Five Forces Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION5.1 Type5.1.1 Carrier Testing5.1.2 Diagnostic Testing5.1.3 Newborn Screening5.1.4 Predictive and Presymptomatic Testing5.1.5 Prenatal Testing5.1.6 Nutrigenomic Testing5.2 Disease5.2.1 Alzheimers Disease5.2.2 Cancer5.2.3 Cystic Fibrosis5.2.4 Sickle Cell Anemia5.2.5 Duchenne Muscular Dystrophy5.2.6 Thalassemia5.2.7 Huntingtons Disease5.2.8 Special Disease5.2.9 Other Diseases5.3 Technology5.3.1 Cytogenetic Testing5.3.2 Biochemical Testing5.3.3 Molecular Testing5.4 Geography5.4.1 Europe5.4.1.1 Germany5.4.1.2 United Kingdom5.4.1.3 France5.4.1.4 Italy5.4.1.5 Spain5.4.1.6 Rest of Europe

6 COMPETITIVE LANDSCAPE6.1 Company Profiles6.1.1 Illumina Inc.6.1.2 Abbott Laboratories6.1.3 23andMe Inc.6.1.4 F. Hoffmann-La Roche Ltd6.1.5 Qiagen6.1.6 Blueprint Genetics Oy6.1.7 Eurofins Scientific6.1.8 Centogene AG6.1.9 Thermo Fisher Scientific6.1.10 Elitech Group

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Marble Flooring Market Size and Growth Insights by Global Key Players 2020 Evolving Technologies with Market Dynamics, Opportunities, Industry Trends Forecast to 2026

Kefir Market Growth Analysis 2020 Global Manufacturing Share, Industry Size, Expected Revenue with CAGR, Emerging Trends, and Industry Updates Forecast by 2023

Mobile and Wireless Backhaul Equipment Market Size 2020 Global Industry Share, Share, Demand, Key Findings, Regional Analysis, Key Players Profiles, Future Prospects and Forecasts to 2023

Lithium Hydroxide Market Size and Share Forecast to 2024 | Global Industry Analysis by Dynamics Trends, Company Overview, Growth Factors

Mobile Camera Chip Market 2020 Industry Outlook by Business Growth, Industry Price Trend, Size Estimation, Report Latest Research, Business Analysis and Forecast Research till 2025

AC Electrical Film Capacitor Market by Major Drivers 2020 Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Value and Forecasts till 2026

See the original post here:
Europe Genetic Testing Market 2020 | Research Objectives and Methodology, Growth Analysis, Top Manufacturers Sales, and Cost Structures Forecast 2024...

23andMe and GSK Head to Clinical Trials With Cancer Drug – Bloomberg

A 23andMe Inc. DNA genetic testing kit.

Photographer: Cayce Clifford/Bloomberg

Photographer: Cayce Clifford/Bloomberg

U.K. drugmaker GlaxoSmithKline Plc and genetic-testing giant 23andMe Inc. have begun their first joint human clinical trial as part of a collaboration to leverage the Silicon Valley firms DNA database to develop drugs.

The companies said that they enrolled their first patientthis month in early-stage trials for a drug that targets human tumors. The drug is an antibody that works to block CD96, a proteinthat plays a role in modulating the bodys immune responses. The theory is that blocking it will help control the activity of another molecule in the body called CD155 that is often over-expressed in malignant human tumors.

GSK took a $300 million stake in 23andMe in 2018in a deal to share its data and collaborate on drug development.The idea was to comb DNA data and health information volunteered by 23andMes more than 12 million customersto hunt for clues as to the role genetics playin different diseases and then translate those insights into potential new drugs.

This is a new way of thinking about drug development, Hal Barron, GSKs chief scientific officer and president of research and development, said in an interview. And the concept is coming to bear.

There is much enthusiasm in the pharmaceutical world for the pathway that these companies are targeting. Prior to teaming up, both had their own programs to explore CD96. 23ndMe tapped into its database to validate GSKs approach, using an algorithm that compared potential drug targets to a data set that included genetic information along with other health data shared by customers in order to identify genetic patterns.

Its an important target, Barron said. Hopefully well find out in the clinic that it helps patients fight cancer, and maybe even aids the immune system in eradicating it. That would be the ideal situation.

The two companies have nearly 30 programs underway exploring potential drug targetsin oncology, immunology, neurology, cardiovascular and metabolic disease. The vast majority are still in the early stages of validating those molecular pathways; for a few, drug discovery efforts are already underway.

What has surprised me the most is how well this approach has worked, how productive its been, said 23andMe Chief Executive Officer Anne Wojcicki.

Identifying a molecular pathway that plays a role in a disease is only part of the hurdle in developing a drug. Even once its clear that a target is involved in a disease, altering it could have other negative health impacts or simply be difficult to design a drug due to the intricacies of human biology.

While its unlikely all thosewill make it to clinical trials, Barron said thatusing genetics to find potential drug targets will hopefully lead to a higher probability thoseultimately result in effective medicines.

23andMe launched its therapeutics program five years ago, and its become an increasingly large focus of the company. In January, it licensed an antibody it had developed to treat inflammatory diseases to Spanish drugmaker Almirall SA. The company is individually pursuing other drug candidates, some of which it may put through clinical trials itself rather than licensing out to other companies.

Before it's here, it's on the Bloomberg Terminal.

Here is the original post:
23andMe and GSK Head to Clinical Trials With Cancer Drug - Bloomberg

Exercise Can Help Ease Excessive Fatigue in Survivors of Cancer – Curetoday.com

Exercise can help prevent excess fatigue for survivors of cancer and other issues are explored in this summer issue of CURE.

Unlike tiredness from a hard day at work or a vigorous workout, cancer fatigue can be unrelated to a persons activities yet all encompassing. The phenomenon can be difficult for those who have never had cancer to understand.

(Friends) really do not get it when I need to go home and climb into bed immediately or am unable to take one more step or have to cancel an engagement, Jane Biehl, a CURE Voices contributor, wrote in a May 15 blog. Before cancer, willpower carried me through fatigue, but no more. That weight all over my body frankly kicks my butt.

In this issue of CURE, we take an in-depth look at cancer fatigue, its causes and a variety of treatment options. Perhaps counterintuitively, experts point out that the most effective therapy for this condition is exercise, a remedy that could seem daunting. Research consistently supports this idea, and our article describes the kinds of programs that work best.

In another feature, we tackle the topic of radiopharmaceuticals, radioactive drugs with an expanding role in both treatment and diagnosis. The expectation is that more of these drugs will be discovered over the next decade, and additional uses will be found for those already on the market. Our article discusses the fascinating area called theranostics or using the same radiopharmaceutical to both diagnose and treat a specific cancer.

Elsewhere in the treatment arena, we bring highlights from Junes annual meeting of the American Society of Clinical Oncology, including findings in colorectal, bladder, ovarian and non-small cell lung cancers. This issue also covers investigational treatments for chronic lymphocytic leukemia and kidney cancer.

At the other end of the spectrum, we look at the time before cancer develops and how people can protect themselves. With the help of a Northwestern University expert in epidemiology and cancer prevention, we examine recommended strategies for avoiding the disease. A separate piece explores whether those who had genetic testing years ago should repeat the process using todays more sophisticated tests to get a more comprehensive picture of whether they have any inherited cancer-causing genes.

Finally, we come full circle with another article on easing a side effect, in this case hair loss during chemotherapy. In an interview, an oncology expert answers our questions about the safety, effectiveness and availability of cold caps.

We hope that these articles, which span the cancer journey from prevention to survivorship, leave you better informed about strategies that can help you lead a healthier and more comfortable life. As always, thank you for reading.

Original post:
Exercise Can Help Ease Excessive Fatigue in Survivors of Cancer - Curetoday.com

COVID-19 Impact on Direct-To-Consumer (DTC) Genetic Testing Market 2020- future development, manufacturers, trends, share, size and forecast details…

In its recently published report, Report Ocean has provided unique insights about the Direct-To-Consumer (DTC) Genetic Testing Market. The main objectives of this research report is to categorize the various dynamics of the market and to offer latest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the Direct-To-Consumer (DTC) Genetic Testing Market.

This research report offers in-depth study about Market Size and Share, Product and Services, Company Profile, Regional Forecast, Consumer Preference, Market Competition, and Industry Chain Structure.

This research report represents the statistical data in the form of TABLES, CHARTS, and infographics to assess the market, its growth and development, and market trends of the Direct-To-Consumer (DTC) Genetic Testing Market during the forecasted period.

COVID 19 Impact on Direct-To-Consumer (DTC) Genetic Testing Market

The Coronavirus Pandemic (COVID-19) has affected every aspect of life worldwide. Under COVID-19 Outbreak, how the Direct-To-Consumer (DTC) Genetic Testing Market will develop is also analyzed in detail in Chapter 1.7 of the report.

In Chapter 2.4, we analyzed industry trends in the context of COVID-19.

In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets.

In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries.

In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=mai28982

Competitive Landscape:

Key players in the global Direct-To-Consumer (DTC) Genetic Testing market covered in Chapter 4:Myriad GeneticsMD RevolutionDeCODEme23andMeGenetrainerGeneByGeneDNA DTCGenecodebook OyNavigenicsThis report also outlines the Major companies or players involved in the Direct-To-Consumer (DTC) Genetic Testing Market, along with product specifications, revenue generated, pricing strategies, contact information, information related to raw materials, equipment and demands. With the help of tables and figures, valuable insights on production, value, price, and gross margin of each player are offered.

Market Segmentation:

The segmentation study is considered as the key section to decide the target market with keen study of segments or smaller sections such as geographical regions, application and product type to optimize advertising technique and marketing strategies at regional as well as global level of the Direct-To-Consumer (DTC) Genetic Testing Market.

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2020-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:

North America (Covered in Chapter 6 and 13)

United States

Canada

Mexico

Europe (Covered in Chapter 7 and 13)

Germany

UK

France

Italy

Spain

Russia

Others

Asia-Pacific (Covered in Chapter 8 and 13)

China

Japan

South Korea

Australia

India

Southeast Asia

Others

Middle East and Africa (Covered in Chapter 9 and 13)

Saudi Arabia

UAE

Egypt

Nigeria

South Africa

Others

South America (Covered in Chapter 10 and 13)

Brazil

Argentina

Columbia

Chile

Others

Some of the Major Highlights of TOC covers:

Report Overview

Study Scope

Key Market Segments

Regulatory Scenario by Region/Country

Market Investment Scenario Strategic

Global Market Growth Trends

Industry Trends

SWOT Analysis

Porters Five Forces Analysis

Potential Market and Growth Potential Analysis

Industry News and Policies by Regions

Industry News

Industry Policies

Industry Trends Under COVID-19

Value Chain of Direct-To-Consumer (DTC) Genetic Testing Market

Value Chain Status

Direct-To-Consumer (DTC) Genetic Testing Market Manufacturing Cost Structure Analysis

Production Process Analysis

Manufacturing Cost Structure of Direct-To-Consumer (DTC) Genetic Testing Market

Labor Cost of Direct-To-Consumer (DTC) Genetic Testing Market

Labor Cost of Direct-To-Consumer (DTC) Genetic Testing Market Under COVID-19

Sales and Marketing Model Analysis

Downstream Major Customer Analysis (by Region)

Value Chain Status Under COVID-19

Direct-To-Consumer (DTC) Genetic Testing Market Production, Revenue (Value), Price Trend by Type

Production and Market Share by Type

Revenue and Market Share by Type

Price by Type

Direct-To-Consumer (DTC) Genetic Testing Market Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Country

Production, Revenue, Price and Gross Margin

Industrial Chain, Sourcing Strategy and Downstream Buyers

Direct-To-Consumer (DTC) Genetic Testing Market Industrial Chain Analysis

Raw Materials Sources of Direct-To-Consumer (DTC) Genetic Testing Market major Players in 2019

Downstream Buyers

Direct-To-Consumer (DTC) Genetic Testing Market Forecast

Direct-To-Consumer (DTC) Genetic Testing Market Sales, Revenue and Growth Rate

Direct-To-Consumer (DTC) Genetic Testing Market Production, Consumption, Export and Import Forecast by Region

Direct-To-Consumer (DTC) Genetic Testing Market Production, Revenue and Price Forecast by Type

Direct-To-Consumer (DTC) Genetic Testing Market Consumption Forecast by Application

Direct-To-Consumer (DTC) Genetic Testing Market Forecast Under COVID-19

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2026

For more information and discount on this report, ask your query at:https://www.reportocean.com/industry-verticals/sample-request?report_id=mai28982

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Matthew SEmail:[emailprotected]

The rest is here:
COVID-19 Impact on Direct-To-Consumer (DTC) Genetic Testing Market 2020- future development, manufacturers, trends, share, size and forecast details...

Myriad Launches Proprietary AMPLIFY Technology, Further Increasing the Performance of its Prequel NIPS Test – GlobeNewswire

SALT LAKE CITY, July 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched its proprietary AMPLIFY technology, which further increases the performance of its Prequelnoninvasive prenatal screening (NIPS) test. The proprietary AMPLIFY process increases the fetal fraction of a NIPS sample by preferentially sequencing the fetal cell-free DNA fragments that circulate in a mothers blood. AMPLIFY technology enables more accurate detection of fetal chromosome abnormalities. In the analytical validation involving samples from more than 1,000 pregnant women, fetal fraction is 2.3 times greater on average with AMPLIFY than with standard NIPS. This improvement reduces false positive and false negative resultsincluding for common aneuploidies, expanded aneuploidies, microdeletions and a babys sex. For instance, false negative performance in common aneuploidies improves 45x with AMPLIFY technology. Additionally, no samples powered by AMPLIFY technology had a fetal fraction below four percent. Other laboratories may fail samples with less than four percent fetal fraction.

Prequel already provided highly accurate results and this proprietary technology further increases the sensitivity of our test, said Nicole Lambert, president of Myriad International, Oncology and Womens Health. With AMPLIFY, Prequel maintains an industry-leading low rate of failed samplesdelivering results to 99.9 percent of patients. The important clinical benefits are that each woman who receives the test can expect highly accurate NIPS results, regardless of body mass index (BMI), race, or ethnicity.

Up to 50 percent of pregnant women present with high BMI to their healthcare provider. Studies have demonstrated that BMI is not evenly distributed across ethnicities, and up to 24 percent of women with high BMI will not receive a result on standard NIPS platforms due to low fetal fraction. Women who dont receive a result may do no further prenatal screening at all; they may go through subsequent rounds of NIPS, or they may undergo invasive procedures such as an amniocentesis or chorionic villus sampling, which can increase the risk of miscarriage and add unnecessary expense to the US healthcare system. Prequel with AMPLIFY technology overcomes the limitations of standard NIPS in order to provide equity of care to pregnant women.

About Prequel Prenatal ScreenThe Myriad Prequel Prenatal Screen is a non-invasive prenatal screen (NIPS) that uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for chromosome abnormalities, such as Down syndrome. Compared to screening methods which use maternal age, ultrasound and serum screening, Prequel has been shown to be superior than by achieving a lower false-positive rate and false-negative rate than these other methods. Among other NIPS, Prequel has an industry leading test failure rate of 0.1 percent. The Prequel Prenatal Screen can be ordered with the Foresight Carrier Screen and offered to all women, including those with high body mass index, and ovum donor or a twin pregnancy.

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to launch of the Companys proprietary AMPLIFY technology; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Visit link:
Myriad Launches Proprietary AMPLIFY Technology, Further Increasing the Performance of its Prequel NIPS Test - GlobeNewswire

Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center. – Physician’s Weekly

Prior studies suggest that referral to genetic counseling and completion of genetic testing vary by race/ethnicity; however, the data are limited.We sought to evaluate patterns of genetic testing and clinical outcomes across race/ethnicity at a hereditary breast and ovarian cancer center.The medical records for all patients undergoing genetic assessment at a hereditary breast and ovarian cancer center were reviewed and stratified by self-reported race/ethnicity (non-Hispanic White, Hispanic, non-Hispanic Black, and Asian).A total of 1666 patients met inclusion criteria (non-Hispanic Whites, 1367; Hispanics, 85, non-Hispanic Blacks, 101; Asians, 113).Demographics, patient characteristics, and referral patterns for patients who underwent genetic testing were analyzed using Kruskal-Wallis tests, chi-square test, or Fishers exact tests, stratifying by self-reported race/ethnicity. Pathogenic mutations and variants of unknown significance (VUS) were reviewed. Outcomes of patients with genetic mutations and personal history of breast and/or gynecologic malignancies were compared.Non-Hispanic Whites were more likely to be referred due to family cancer history compared to all other ethnicities while Non-Hispanic Blacks, Hispanics, and Asians were more likely to be referred due to personal history of cancer (p<0.001). Non-Hispanic Blacks and Hispanics were more likely to have advanced-stage cancer at the time of genetic testing (p<0.02). Rates of mutations did not differ by race/ethnicity when Ashkenazi Jewish patients were excluded (p=0.08). Among patients found to have a BRCA1/2 mutation, Non-Hispanic Whites were more likely to undergo cancer screening and risk-reducing surgery compared with all other ethnicities (p=0.04).Minority patients were more likely to utilize genetic services following a cancer diagnosis and less likely due to family cancer history, suggesting a missed opportunity for mutation detection and cancer prevention in this population. Efforts to eradicate racial/ethnic disparities in early access to genetic testing and guided cancer prevention strategies are essential.

PubMed

See more here:
Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center. - Physician's Weekly

Worldwide Hereditary Genetic Testing Industry to 2030 – Rise of Direct-to-Consumer Testing Services Presents Opportunities – ResearchAndMarkets.com -…

DUBLIN--(BUSINESS WIRE)--The "Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Hereditary genetic testing has grown significantly since the technology was first commercialized, but it is important to quantify that growth and describe future trends. The genome testing industry is proliferating, and its growth is expected to continue at its torrid pace. However, there are significant challenges that may dampen future growth if not addressed.

Our healthcare experts have found hereditary genetic testing to be one of the most rapidly evolving technologies, and the global market for hereditary genetic testing is predicted to grow at a CAGR of 13.59% over the forecast period of 2020-2030.

The unmet clinical needs for better tools to predict, diagnose, treat, and monitor disease are acting as significant factors driving the growth of the sequencing industry. Other factors driving the growth include the increased understanding of the molecular basis of disease, patient demand, industry investment, and regulations that allow marketing of tests without FDA approval.

Despite rapid advanced sequencing industry growth, there are several key issues that are needed to be addressed to facilitate future growth. The relatively high total costs of delivering sequencing test results compared with other technology platforms, and limited coverage by payers, are the key challenges to the growth of this industry. Whole-genome and exome sequencing remain relatively costly requiring initial equipment investment, specialized workforce requirements, and time-intensive variant interpretation.

Within the research report, the market is segmented on the basis of oncology genetic testing, cardiology genetic testing, neurology genetic testing, product, sample, application area, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Market Dynamics

Drivers

Challenges

Opportunities

Key Questions Answered in this Report:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/ry89nq

View post:
Worldwide Hereditary Genetic Testing Industry to 2030 - Rise of Direct-to-Consumer Testing Services Presents Opportunities - ResearchAndMarkets.com -...

The Vital Role Genetic Testing Plays in Bladder Cancer Treatments – Cancer Therapy Advisor

Sponsored Content by the Janssen Pharmaceutical Companies of Johnson & Johnson

Recent research suggests cancer patients who have undergone genetic testing for inherited or acquired mutations were more likely to have prolonged overall survival than patients who did not, as genetic tests can direct healthcare providers to targeted treatment paradigms featuring therapies specific to an individuals genetic makeup.1,2

Various genetic alterations impact how specific tumors can arise or develop, including BRCA1/2, p53, HER2 and the RAS family of genes, among others.3 As researchers continue to study how genetic changes impact cancer development, findings have led to improvements in cancer care including the increased use of targeted therapies and early detection strategies.3

Treating with an inhibitor or a targeted therapy may slow or halt uncontrolled cell growth that may be driven, in part, by a genetically-altered cancer and can provide clinical benefits to patients, said Tracy McGowan, MD, Strategic Area Lead for Medical Affairs at Janssen Biotech, Inc. Analyzing a patients DNA or RNA for actionable genetic alterations can help direct a cancer patients treatment plan, and is intended to provide patients and providers with treatment options that are specific to the unique characteristics of an individuals specific tumor type.

An example of the above is the fibroblast growth factor receptor (FGFR) genetic alteration, which occurs in approximately one in five patients with metastatic urothelial carcinoma (mUC).4,5 FGFR genes, a family of receptor tyrosine kinases, impact tumor cell proliferation, migration and survival in both non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) including mUC.6 This is also true in a variety of other tumor types as well.4

Dr. McGowan is hopeful that, over time, more healthcare providers will recommend genetic testing earlier in the course of bladder cancer to ensure that appropriate treatment options are available for consideration. In the evolving era of precision medicine, it is important to inform patients and their families about the role of genetic testing to help them navigate treatment opportunities. For healthcare providers, talking to patients about the role of genetic testing in their care plan is the beginning of important conversations especially when specific targeted therapies are now available.

References

Visit link:
The Vital Role Genetic Testing Plays in Bladder Cancer Treatments - Cancer Therapy Advisor

Dr. Rana on the Rationale for Video Genetic Counseling in Prostate Cancer – OncLive

Huma Q. Rana, MD, MPH, discusses the rationale for the ProGen trial, which compared the effectiveness of video education versus in-person genetic counseling for men with prostate cancer.

Huma Q. Rana, MD, MPH, anassistant professor of medicine at Harvard Medical School andclinical directorofCancer Genetics and Prevention at Dana-Farber Cancer Institute, discusses the rationale for the ProGen trial, which compared the effectiveness of video education versus in-person genetic counseling for men with prostate cancer.

There are increasing indications for germline genetic testing in prostate cancer, says Rana. Through several clinical studies, the field has recognized that there is a high prevalence of inherited mutations among men with advanced prostate cancers, and this could have significant implications on treatment. Men with advanced prostate cancer, particularly those with underlying mutations in genes such asBRCA2, are known to have poor outcomes, says Rana. Therefore, it is important to identify these men and make matched targeted therapy available to them and their oncologists.

In recognizing that prostate cancer is a very common disease and that traditional germline genetic testing would be very difficult to implementpotentially overwhelming already strained systems for genetic testinga randomized controlled trialwas conducted. In the trial, investigators compared the effectiveness of a short videothat focused on the educational components of a genetic counseling visit with in-person genetic counseling for men with potentially lethal prostate cancers, concludes Rana.

View original post here:
Dr. Rana on the Rationale for Video Genetic Counseling in Prostate Cancer - OncLive

Predictive Genetic Testing And Consumer (Wellness) Genomics Industry Market Size | Global Industry Analysis, Segments, Top Key Players, Drivers and…

Global Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market Report 2020 presents critical information and factual data about the Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market, providing an overall statistical study of this market on the basis of market drivers, market limitations, and its future prospects. The widespread Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market opportunities and trends are also taken into consideration in Predictive Genetic Testing And Consumer (Wellness) Genomics Industry industry. with growth trends, various stakeholders like investors, traders, suppliers, SWOT analysis Opportunities and Threat to the organization and others.

The Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market report comprises of the key trends which influence the industry growth with respect to the regional terrain and competitive arena. The study highlights the opportunities that will support the industry expansion in existing and untapped markets along with the challenges the business sphere will face. Besides this, the report also offers an intricate analysis of case studies including those of COVID-19 pandemic, with the aim to provide a clear picture of this industry vertical to all shareholders.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/27761

Pivotal pointers from COVID-19 impact assessment:

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/27761

Analysis of the regional terrain:

Highlights of the Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market report:

Key Coverage of report:

Impact of the latest technological innovations on the Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market

Key growth strategies adopted by the prominent market players to address the challenges and restraints put forward by the COVID-19 pandemic

Historical and current trends likely to affect the overall market dynamics of the Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market

Growth assessment of the various market segments over the forecast timeline

Regional and global presence of major market players in the Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market

Table of Content:

1 Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market Introduction and Market Overview

1.1 Objectives of the Study

1.2 Overview of Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market

1.3 Scope of The Study

1.3.1 Key Market Segments

1.3.2 Players Covered

1.3.3 COVID-19's impact on the Predictive Genetic Testing And Consumer (Wellness) Genomics Industry industry

1.4 Methodology of The Study

1.5 Research Data Source

2 Executive Summary

2.1 Market Overview

2.1.1 Global Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market Size, 2015 - 2020

2.1.2 Global Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market Size by Type, 2015 - 2020

2.1.3 Global Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market Size by Application, 2015 - 2020

2.1.4 Global Predictive Genetic Testing And Consumer (Wellness) Genomics Industry market Size by Region, 2015 - 2025

2.2 Business Environment Analysis

2.2.1 Global COVID-19 Status and Economic Overview

2.2.2 Influence of COVID-19 Outbreak on Predictive Genetic Testing And Consumer (Wellness) Genomics Industry Industry Development

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/27761

Read the original post:
Predictive Genetic Testing And Consumer (Wellness) Genomics Industry Market Size | Global Industry Analysis, Segments, Top Key Players, Drivers and...

Preimplantation Genetic Testing Market Market Dynamics, Opportunities and Risks 2027 – Owned

New Jersey, United States,- The research report on Preimplantation Genetic Testing market comprises of insights in terms of pivotal parameters such as production as well as the consumption patterns alongside revenue estimations for the projected timeframe. Speaking of production aspects, the study offers an in-depth analysis regarding the manufacturing processes along with the gross revenue amassed by the leading producers operating in this business arena. The unit cost deployed by these producers in various regions during the estimated timeframe is also mentioned in the report.

Significant information pertaining to the product volume and consumption value is enlisted in the document. Additionally, the report contains details regarding the consumption graphs, Individual sale prices, and import & export activities. Additional information concerning the production and consumption patterns are presented in the report.

In market segmentation by manufacturers, the report covers the following companies-

Exploring the growth rate over a period

Business owners looking to scale up their business can refer this report that contains data regarding the rise in sales within a given consumer base for the forecast period, 2020 to 2027. Product owners can use this information along with the driving factors such as demographics and revenue generated from other products discussed in the report to get a better analysis of their products and services. Besides, the research analysts have compared the market growth rate with product sales to enable business owners to determine the success or failure of a specific product or service.

By Type

By Application

Regions Covered in the Global Preimplantation Genetic Testing Market:

The Middle East and Africa (GCC Countries and Egypt)

North America (the United States, Mexico, and Canada)

South America (Brazil etc.)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Highlights of the Report:

Accurate market size and CAGR forecasts for the period 2020-2026

Identification and in-depth assessment of growth opportunities in key segments and regions

Detailed company profiling of top players of the global Preimplantation Genetic Testing market

Exhaustive research on innovation and other trends of the global Preimplantation Genetic Testing market

Reliable industry value chain and supply chain analysis

Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

The scope of the Report:

The report offers a complete company profiling of leading players competing in the global Preimplantation Genetic Testing marketwith a high focus on the share, gross margin, net profit, sales, product portfolio, new applications, recent developments, and several other factors. It also throws light on the vendor landscape to help players become aware of future competitive changes in the global Preimplantation Genetic Testing market.

Reasons to Buy the Report:

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

See more here:
Preimplantation Genetic Testing Market Market Dynamics, Opportunities and Risks 2027 - Owned

Things to Know About Immunotherapy Clinical Trials Pancreatic Cancer Action Network – Pancreatic Cancer News & Stories

Editors note: Jeopardy! host Alex Trebek and former Sen. Harry Reid have publicly mentioned being treated with an experimental immunotherapy combination for their pancreatic cancer. The Pancreatic Cancer Action Network (PanCAN) strongly recommends clinical trials for all pancreatic cancer patients. Learn more below about immunotherapy and other types of clinical trials aiming to improve pancreatic cancer patient outcomes.

Pancreatic cancer patients who participate in clinical research have better outcomes. And every treatment available today was approved through a clinical trial. PanCAN therefore strongly recommends clinical trials at diagnosis and during every treatment decision.

Contact PanCANs Patient Services for questions about pancreatic cancer treatment and clinical trials, including a personalized clinical trials search.

There are approximately 170 pancreatic cancer clinical trials currently enrolling patients across the U.S. (Please note that some trials have been affected by the coronavirus disease pandemic and may have been modified or put on hold.)

The goals of pancreatic cancer clinical trials is to determine whether experimental treatment options are safe for patients and more effective than the current standard of care.

Clinical trials may test an experimental drug, treatment approach or combination. They may include standard drugs or approaches (e.g., chemotherapy, surgery or radiation therapy). The experimental approach is compared to the best available standard of care.

Immunotherapy has revolutionized the treatment of some solid tumors, but the strategy has shown limited effectiveness in most pancreatic cancer patients to date.

Immunotherapy involves activating and training the patients immune system to recognize and attack cancer cells. Turning on the patients immune system is often not enough, however cancer cells and their surrounding microenvironment can often block an immune attack. So, many immunotherapeutic approaches include stopping this evasion in addition to activating the immune system.

One type of immunotherapy that has been approved to treat some pancreatic cancer patients is called Keytruda (pembrolizumab). Keytruda has been shown to be effective in patients with pancreatic cancer and other solid tumors with certain molecular features.

Basing treatment on a patients biology is known as precision medicine. PanCAN strongly recommends all pancreatic cancer patients get tested both biomarker tumor tissue testing and genetic testing for inherited mutations to determine whether certain treatments may be especially effective for them. Both types of test are available through PanCANs Know Your Tumor precision medicine service.

Other types of immunotherapy are being tested in patients regardless of their biology.

The experimental treatment combination that Trebek and Reid have mentioned involves several experimental immunotherapy drugs in combination with standard treatments. Clinical trials are underway to determine whether this treatment combination is safe and effective in patients with pancreatic cancer.

We are grateful to both Trebek and Reid for bringing awareness to the disease and to the need for more and more effective treatment options for patients. More data will be necessary to determine whether the experimental treatment theyre receiving is better than standard of care options.

Read more from the original source:
Things to Know About Immunotherapy Clinical Trials Pancreatic Cancer Action Network - Pancreatic Cancer News & Stories

Research on Direct-to-consumer Genetic Testing Market (impact of COVID-19) with Top Players: Myriad Genetics, Inc., 23andMe, Inc., Invitae, Ambry…

Global Direct-to-consumer Genetic Testing Market: Trends Estimates High Demand by 2027

The Direct-to-consumer Genetic Testing Market 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The Direct-to-consumer Genetic Testing Industry Report is an in-depth study analyzing the current state of the Direct-to-consumer Genetic Testing Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Direct-to-consumer Genetic Testing Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape.

The last section of the report focuses on the extensive competitive landscape, which includes some of the details of prominent players of the Direct-to-consumer Genetic Testing market. It also covers the strategies adopted by these players for retaining their dominance in the market. These strategies may involve mergers and acquisitions, partnerships, collaborations, investment in research and developments (R&Ds), new product launches, and business expansion. It helps to keep an eye on recent development in the market including product innovation and new product approvals by the government authorities.

The final report will add the analysis of the Impact of Covid-19 in this report Direct-to-consumer Genetic Testing industry.

Major Companies Covered in Research Report: Myriad Genetics, Inc., 23andMe, Inc., Invitae, Ambry Genetics, Laboratory Corporation of America, African Ancestry, MyHeritage, AncestrybyDNA, Counsyl, Inc., Pathway Genomics, DNA Services of America, Positive Bioscience Ltd., Quest Diagnostics, Sonora Quest Laboratories, Gene by Gene, and Mapmygenome.

Get a Free Sample [emailprotected] https://www.reportsandmarkets.com/sample-request/global-direct-to-consumer-genetic-testing-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=primefeed&utm_medium=33

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the Direct-to-consumer Genetic Testing Market; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and development plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

Global Direct-to-consumer Genetic Testing Market Research Report 2020 carries in-depth case studies on the various countries which are involved in the Direct-to-consumer Genetic Testing market. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

What questions does the Direct-to-consumer Genetic Testing market report answer pertaining to the regional reach of the industry

The report claims to split the regional scope of the Direct-to-consumer Genetic Testing market into North America, Europe, Asia-Pacific, South America & Middle East and Africa. Which among these regions has been touted to amass the largest market share over the anticipated duration

How do the sales figures look at present How does the sales scenario look for the future

Considering the present scenario, how much revenue will each region attain by the end of the forecast period

How much is the market share that each of these regions has accumulated presently

How much is the growth rate that each topography will depict over the predicted timeline

A short overview of the Direct-to-consumer Genetic Testing market scope:

Global market remuneration

Overall projected growth rate

Industry trends

Competitive scope

Product range

Application landscape

Supplier analysis

Marketing channel trends Now and later

Sales channel evaluation

Market Competition Trend

Market Concentration Rate

Reasons for Read this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

Chapter 1:Direct-to-consumer Genetic Testing Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Direct-to-consumer Genetic Testing Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Direct-to-consumer Genetic Testing Market Effect Factors Analysis

Chapter 12: GlobalDirect-to-consumer Genetic Testing Market Forecast to 2027

To Know More of This Report @ https://www.reportsandmarkets.com/enquiry/global-direct-to-consumer-genetic-testing-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=primefeed&utm_medium=33

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read the original here:
Research on Direct-to-consumer Genetic Testing Market (impact of COVID-19) with Top Players: Myriad Genetics, Inc., 23andMe, Inc., Invitae, Ambry...

Point-of-Care Genetic Testing Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis And Forecast…

DataIntelo, one of the worlds prominent market research firms has announced a novel report on Global Point-of-Care Genetic Testing Market. The report contains vital insights on the market which will support the clients to make the right business decisions. This research will help both existing and new aspirants for Point-of-Care Genetic Testing market to figure out and study the market needs, market size, and competition. The report incorporates data regarding the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities, and the threats faced by key players during the forecast period of 2020-2027.

Get A Free Sample Report @ https://dataintelo.com/request-sample/?reportId=46729

Impact of COVID-19 on Point-of-Care Genetic Testing Market

The report also includes the impact of ongoing global crisis i.e. COVID-19 on the Point-of-Care Genetic Testing market and what the future holds for it. It provides an analysis of the effects of the pandemic on the global economy. The outbreak has directly disturbed the demand and supply chain. The report also analyzes the financial impact on firms and financial markets. DataIntelo has gathered insights from several delegates of the industry and got involved in the primary and secondary research to provide the clients with data and strategies to combat the market challenges during and after COVID-19 pandemic.

Benefits of buying the report:

Industry experts and research analysts have worked extensively to prepare the research report which will help you to give that extra edge in the competitive market. The market research report can be customized according to you to your needs. This means that DataIntelo can cover a particular product, application, or can provide a detailed analysis in the report. You can also purchase a separate report for a specific region.

You can buy the complete report @ https://dataintelo.com/checkout/?reportId=46729

Some of the major companies that are covered in this report:

Roche (Switzerland)Thermo Fisher Scientific (US)Cepheid (US)IQuum (US)Biocartis (Switzerland)Idaho Technologies (US)

*Note: Additional companies can be included on request

The market scenario is likely to be fairly competitive. To analyze any market with simplicity the market is fragmented into the following segments:

By Application:

Diagnostic LabsBio-Pharmaceutical IndustryAcademic InstitutionsOther

By Type:

Product Type IProduct Type IIProduct Type III

By Geographical Regions

Asia Pacific: China, Japan, India, and Rest of Asia PacificEurope: Germany, the UK, France, and Rest of EuropeNorth America: The US, Mexico, and CanadaLatin America: Brazil and Rest of Latin AmericaMiddle East & Africa: GCC Countries and Rest of Middle East & Africa

Segmenting the market into smaller components helps in analyzing the dynamics of the market with more clarity. Another key component that is included in the report is the regional analysis to assess the global presence of the Point-of-Care Genetic Testing market. You can also opt for a yearly subscription of all the updates on the Point-of-Care Genetic Testing market.

Request a sample before buying this report @ https://dataintelo.com/request-sample/?reportId=46729

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Point-of-Care Genetic Testing Market Overview

Point-of-Care Genetic Testing Supply Chain Analysis

Point-of-Care Genetic Testing Pricing Analysis

Global Point-of-Care Genetic Testing Market Analysis and Forecast by Type

Global Point-of-Care Genetic Testing Market Analysis and Forecast by Application

Global Point-of-Care Genetic Testing Market Analysis and Forecast by Sales Channel

Global Point-of-Care Genetic Testing Market Analysis and Forecast by Region

North America Point-of-Care Genetic Testing Market Analysis and Forecast

Latin America Point-of-Care Genetic Testing Market Analysis and Forecast

Europe Point-of-Care Genetic Testing Market Analysis and Forecast

Asia Pacific Point-of-Care Genetic Testing Market Analysis and Forecast

Asia Pacific Point-of-Care Genetic Testing Market Size and Volume Forecast by Application

Middle East & Africa Point-of-Care Genetic Testing Market Analysis and Forecast

Competition Landscape

If you have any questions on this report, feel free to reach us! @ https://dataintelo.com/enquiry-before-buying/?reportId=46729

About DataIntelo:

DataIntelo has a vast experience in making customized market research reports in various industry verticals. Our motto is to provide complete client satisfaction. We cover in-depth market analysis, which consists of stipulating lucrative business strategies, especially for the new entrants and the emerging players of the market. We make sure that each report goes through intensive primary, secondary research, interviews, and consumer surveys before final dispatch.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also provide ongoing training and knowledge sharing to keep our analysts tapped into industry best practices and loaded with information.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://dataintelo.com

Natalia is Business Writer Carrying A Vast Experience Over a Decade , She Helps TechinFeed Blog with her Expertise Business Articles

See more here:
Point-of-Care Genetic Testing Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis And Forecast...

How Innovation is Changing the At-home Genetic Testing Market – Market Research Correspondent

In this report, the global At-home Genetic Testing market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The At-home Genetic Testing market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the At-home Genetic Testing market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2601844&source=atm

The key players covered in this study23andMeMyHeritageLabCorpMyriad GeneticsAncestry.comQuest DiagnosticsGene By GeneDNA Diagnostics CenterInvitaeIntelliGeneticsAmbry GeneticsLiving DNAEasyDNAPathway GenomicsCentrillion TechnologyXcodeColor GenomicsAnglia DNA ServicesAfrican AncestryCanadian DNA ServicesDNA Family CheckAlpha BiolaboratoriesTest Me DNA23 MofangGenetic HealthDNA Services of AmericaShuwen Health SciencesMapmygenomeFull Genomes

Market segment by Type, the product can be split intoDiagnostic ScreeningPGDRelationship testingMarket segment by Application, split intoOnlineOffline

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global At-home Genetic Testing status, future forecast, growth opportunity, key market and key players.To present the At-home Genetic Testing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of At-home Genetic Testing are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2601844&source=atm

The study objectives of At-home Genetic Testing Market Report are:

To analyze and research the At-home Genetic Testing market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the At-home Genetic Testing manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions At-home Genetic Testing market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the keyword market.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2601844&licType=S&source=atm

Read the original:
How Innovation is Changing the At-home Genetic Testing Market - Market Research Correspondent

Impact Of Covid-19 On Breast Cancer Predictive Genetic Testing Market Is To Witness Significant Growth Between 2020-2027 With Leading Players Roche,…

DataIntelo offers a detailed report on Global Breast Cancer Predictive Genetic Testing Market. The report is a comprehensive research study that provides the scope of Breast Cancer Predictive Genetic Testing market size, industry growth opportunities and challenges, current market trends, potential players, and expected performance of the market in regions for the forecast period from 2020 to 2027. This report highlights key insights on the market focusing on the possible requirements of the clients and assisting them to make right decision about their business investment plans and strategies.

The Breast Cancer Predictive Genetic Testing market report also covers an overview of the segments and sub-segmentations including the product types, applications, companies and regions. This report further includes the impact of COVID-19 on the market and explains dynamics of the market, future business impact, competition landscape of the companies, and the flow of the global supply and consumption. The report provides an in-depth analysis of the overall market structure of Breast Cancer Predictive Genetic Testing and assesses the possible changes in the current as well as future competitive scenarios of the Breast Cancer Predictive Genetic Testing market.

Request A Free Sample Report @ https://dataintelo.com/request-sample/?reportId=118830

The published report consists of a robust research methodology by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the companies. DataIntelo is known for its data accuracy and granular market reports.

The report is prepared with a group of graphical representations, tables, and figures which displays a clear picture of the developments of the products and its market performance over the last few years. With this precise report, it can be easily understood the growth potential, revenue growth, product range, and pricing factors related to the Breast Cancer Predictive Genetic Testing market. The report also covers the recent agreements including merger & acquisition, partnership or joint venture and latest developments of the manufacturers to sustain in the global competition of the Breast Cancer Predictive Genetic Testing market.

Key companies that are covered in this report:

RocheThermo Fisher ScientificPerkinElmerQuest DiagnosticsMyriad GeneticsIverson GeneticsCancer GeneticsOncoCyte CorporationNeoGenomicsInvitae

*Note: Additional companies can be included on request

The report covers a detailed performance of some of the key players and analysis of major players in the industry, segments, application, and regions. Moreover, the report also considers the governments policies in different regions which illustrates the key opportunities as well as challenges of the market in each region.

By Application:

HospitalsClinicsOther

By Type:

High Penetrant GenesIntermediate Penetrant GenesLow Penetrant Genes

As per the report, the Breast Cancer Predictive Genetic Testing market is projected to reach a value of USDXX by the end of 2027 and grow at a CAGR of XX% through the forecast period (2020-2027). The report describes the current market trend of the Breast Cancer Predictive Genetic Testing in regions, covering North America, Latin America, Europe, Asia Pacific, and Middle East & Africa by focusing the market performance by the key countries in the respective regions. According to the need of the clients, this report can be customized and available in a separate report for the specific region.

You can also go for a yearly subscription of all the updates on Breast Cancer Predictive Genetic Testing market.

You can buy the complete report @ https://dataintelo.com/checkout/?reportId=118830

The following is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Breast Cancer Predictive Genetic Testing Market Overview

Breast Cancer Predictive Genetic Testing Supply Chain Analysis

Breast Cancer Predictive Genetic Testing Pricing Analysis

Global Breast Cancer Predictive Genetic Testing Market Analysis and Forecast by Type

Global Breast Cancer Predictive Genetic Testing Market Analysis and Forecast by Application

Global Breast Cancer Predictive Genetic Testing Market Analysis and Forecast by Sales Channel

Global Breast Cancer Predictive Genetic Testing Market Analysis and Forecast by Region

North America Breast Cancer Predictive Genetic Testing Market Analysis and Forecast

Latin America Breast Cancer Predictive Genetic Testing Market Analysis and Forecast

Europe Breast Cancer Predictive Genetic Testing Market Analysis and Forecast

Asia Pacific Breast Cancer Predictive Genetic Testing Market Analysis and Forecast

Middle East & Africa Breast Cancer Predictive Genetic Testing Market Analysis and Forecast

Competition Landscape

Why you should buy this report?

This report offers a concise analysis of the Breast Cancer Predictive Genetic Testing market for the last 5 years with historical data & more accurate prediction for upcoming 6 years on the basis of statistical information.

This report helps you to understand the market components by offering a cohesive framework of the key players and their competition dynamics as well as strategies.

The report is a complete guideline for the clients to arrive an informed business decision since it consists of a detailed information for better understandings of the current & future market situation.

The report also answers some of the key questions given below:

Which end-user is likely to play a crucial role in the development of the Breast Cancer Predictive Genetic Testing market?

Which regional market is expected to dominate the Breast Cancer Predictive Genetic Testing market in 2020-2027?

How is consumer consumption behavior impacting the business operations of market players in the current scenario of the Breast Cancer Predictive Genetic Testing market?

If you have any questions on this report, please reach out to us @ https://dataintelo.com/enquiry-before-buying/?reportId=118830

About DataIntelo:

We possess expertise in a variety of business intelligence domains. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also provide ongoing training and knowledge sharing to keep our analysts tapped into industry best practices.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://dataintelo.com

Link:
Impact Of Covid-19 On Breast Cancer Predictive Genetic Testing Market Is To Witness Significant Growth Between 2020-2027 With Leading Players Roche,...

Genetic Testing Market Drivers, Growth Rate Analysis 2020 Global Industry Analysis, Key Venders, Global Trends, Size, Share and Profits Forecast to…

The Genetic Testing market research report 2020 provides an in-depth analysis of significant market dynamics. The report comprehensively emphasizes on drivers, restraints, trends and opportunities prevailing in the global and regional market. The report studies all key market information including revenue, market share, segmentation breakdown. The Genetic Testing market report offers an analysis of the key players with their product offerings, business strategies, and geographical presence.

Global Genetic Testing market size is estimated to grow at a CAGR of over 12% with Revenue USD 4.86billion during the forecast period 2020-2024.

Get a Sample Copy of the Report https://www.industryresearch.co/enquiry/request-sample/14966951

About Genetic Testing Market:

Genetic Testing Market analysis considers sales from both equipment and consumable products. Our study also finds the sales of genetic testing in Asia, Europe, North America, and ROW. In 2019, the equipment segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing workload for performing high-throughput tests in clinical diagnostic facilities will play a significant role in the equipment segment to maintain its market position. Also, our global genetic testing market report looks at factors such as rising prevalence of genetic diseases and disorders, rising approval of advanced genetic testing products, and increasing affordability due to reduction in cost of genetic testing. However, varying regulations on genetic testing and research globally, issues related to product recalls, and lack of trained genetic professionals may hamper the growth of the genetic testing industry over the forecast period.

Some Key Players of Genetic Testing Market Are:

To Understand How Covid-19 Impact is Covered in This Report https://www.industryresearch.co/enquiry/request-covid19/14966951

Market Dynamics of Genetic Testing Market:

Driver: Rising Approval Of Advanced Genetic Testing Products

Trends: Growing Adoption Of Pharmacogenetic Testing In Reducing Adverse Drug Events

Challenges: Lack Of Trained Genetic Professionals

Rising approval of advanced genetic testing products

Commercial applications of genetic screening in human health management and the advent of whole genome sequencing have allowed vendors to offer a variety of innovative products in the global genetic testing market. The use of advanced technologies such as pharmacogenomics and companion diagnostics has helped vendors in assuring the safety of their products. Furthermore, the deployment of rapid and simplified technologies in genetic testing offers several benefits including the reduction in turnaround time, optimum resource use, and accuracy in genetic diagnosis. Thus, the rising approval of advanced genetic testing products will lead to the expansion of the global genetic testing market at a CAGR of over 12% during the forecast period.

Growing adoption of pharmacogenetic testing in reducing adverse drug events

The growing approval of new drug molecules and the rising demand for targeted therapies and personalized medicines have increased the adoption of pharmacogenomic testing by pharmaceutical companies. Pharmacogenomic testing combines the principles of pharmacology and genomics to study the response of an individual to any specific drug. The study of drug-specific responses allows pharmaceutical companies to prevent adverse drug incidence and ensure drug safety and performance during pre and post commercial stages. This development is expected to have a positive impact on the overall market growth.

Genetic Testing Market Segmentation Analysis:

By Type:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/14966951

Genetic Testing Market Report Highlights:

Genetic Testing Market Segment by Regions:

Purchase this Report (Price 2500 USD for single user license) https://www.industryresearch.co/purchase/14966951

Some Points from Genetic Testing Market Report TOC:

PART01:EXECUTIVESUMMARY

PART02:SCOPEOFTHEREPORT

PART03:MARKETLANDSCAPE

PART04:MARKETSIZING

PART05:FIVEFORCESANALYSIS

PART06:MARKETSEGMENTATIONBYTECHNOLOGY

PART07:MARKETSEGMENTATIONBYFURNACETYPE

PART08:CUSTOMERLANDSCAPE

PART09:GEOGRAPHICLANDSCAPE

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

For Detailed TOC Click Here

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Crop Growth Regulators Market 2020 Global Business Growth, Industry Size, Share, Revenue, Trends, Global Market Demand Penetration and Forecast to 2025

Millimeter Wave Scanner Market 2020| Worldwide Overview by Industry Size, Market Share, Future Trends, Growth Factors and Leading Players Research Report Analysis till 2025

Titanium Diboride Powders Market 2020 2026 | Global Industry Manufacturing Size, Share, Business Insights, Development Status, Key Challenges and Forecast Analysis Industry Research.co

Impact/Shock Recorders Market 2020 Current Industry Trends, Global Key Barriers, New Opportunities, Key Players Overview, Evolving Technology by 2024 by Industry Research.co

Graphite Block Market Size Forecast Analysis by Global Opportunities 2020: Development Status, Organization Share, Market Components, and Regional Outlook till 2026

Biliary Stent Market Business Strategy, Development Plans 2020: Trends Analysis, Industry Outlook, Global Opportunities, Market Share and Size, Present Scenario of Manufacturers Forecast to 2026

Original post:
Genetic Testing Market Drivers, Growth Rate Analysis 2020 Global Industry Analysis, Key Venders, Global Trends, Size, Share and Profits Forecast to...

Prenatal and New-born Genetic Testing Market 2020 Size with Top Manufactures are Agilent Technologies, Inc.,Bio-Rad Laboratories, Inc.,Natera,…

Global Prenatal and New-born Genetic Testing Market Report briefly splits the worldwide Prenatal and New-born Genetic Testing market based on product type, various applications, and geographical regions. The data portrayed in the report is collected from various global industrys that help us to calculate the growth of the segments in the forecast period. Apart from this, the report demonstrates the competitive set-up in the global Prenatal and New-born Genetic Testing market.

Get a Sample Copy of report https://www.marketreportsworld.com/enquiry/request-sample/15902182

Prenatal and New-born Genetic Testing Market provides sizing and growth opportunities for the period 2020-2025. Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market. Report Includes a detailed analysis of growth drivers, challenges, and investment opportunities. Delivers a complete overview of segments and the regional outlook of the market. Prenatal and New-born Genetic Testing Market Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain competitive advantage.

To Understand How COVID-19 Impact is Covered in This Report. Get Sample copy of the report at : https://www.marketreportsworld.com/enquiry/request-covid19/15902182

List Of Best KEY PLAYERS in Prenatal and New-born Genetic Testing Market Report are:-

About Prenatal and New-born Genetic Testing Market:

Market Analysis and Insights: Global Prenatal and New-born Genetic Testing MarketThe global Prenatal and New-born Genetic Testing market size is projected to reach US$ 3920 million by 2026, from US$ 3647.2 million in 2020, at a CAGR of 6.9%% during 2021-2026.Global Prenatal and New-born Genetic Testing

Prenatal and New-born Genetic Testing Market By Type:

Prenatal and New-born Genetic Testing Market By Application:

Inquire more and share questions if any before the purchase on this report at https://www.marketreportsworld.com/enquiry/pre-order-enquiry/15902182

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Prenatal and New-born Genetic Testing in these regions, from 2015 to 2025, covering

The study objectives of this report are:

Key Stakeholders

Purchase this report (Price 3900 USD for a single-user license) https://www.marketreportsworld.com/purchase/15902182

Major Points from Table of Contents:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.4.1 Global Prenatal and New-born Genetic TestingMarket Size Growth Rate by Type (2014-2025)1.4.2 Major-Type1.4.3 Independent-Type1.4.4 Administrator-Type1.5 Market by Application1.5.1 Global Prenatal and New-born Genetic TestingMarket Share by Application (2014-2025)1.5.2 Commercial1.5.3 Commonweal1.5.4 Other1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Prenatal and New-born Genetic TestingMarket Size2.2 Prenatal and New-born Genetic TestingGrowth Trends by Regions2.2.1 Prenatal and New-born Genetic TestingMarket Size by Regions (2014-2025)2.2.2 Prenatal and New-born Genetic TestingMarket Share by Regions (2014-2020)2.3 Industry Trends2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Opportunities

3 Market Share by Key Players3.1 Prenatal and New-born Genetic TestingMarket Size by Manufacturers3.1.1 Global Prenatal and New-born Genetic TestingRevenue by Manufacturers (2014-2020)3.1.2 Global Prenatal and New-born Genetic TestingRevenue Market Share by Manufacturers (2014-2020)3.1.3 Global Prenatal and New-born Genetic TestingMarket Concentration Ratio (CR5 and HHI)3.2 Prenatal and New-born Genetic TestingKey Players Head office and Area Served3.3 Key Players Prenatal and New-born Genetic TestingProduct/Solution/Service3.4 Date ofEnterinto Prenatal and New-born Genetic TestingMarket3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application4.1 Global Prenatal and New-born Genetic TestingMarket Size by Type (2014-2020)4.2 Global Prenatal and New-born Genetic TestingMarket Size by Application (2014-2020)

(5, 6, 7, 8, 9, 10, 11) United States, Europe,China,Japan,Southeast Asia,India,Central & South AmericaPrenatal and New-born Genetic TestingMarket Size (2014-2020)Key PlayersPrenatal and New-born Genetic TestingMarket Size by TypePrenatal and New-born Genetic TestingMarket Size by Application

12 International Players ProfilesCompany DetailsCompany Description and Business OverviewPrenatal and New-born Genetic TestingIntroductionRevenue in Prenatal and New-born Genetic TestingBusiness (2014-2020)Recent Development

13 Market Forecast 2020-202513.1 Market Size Forecast by Regions13.2 United States13.3 Europe13.4 China13.5 Japan13.6 Southeast Asia13.7 India13.8 Central & South America13.9 Market Size Forecast by Product (2020-2025)13.10 Market Size Forecast by Application (2020-2025)

14 Analysts Viewpoints/Conclusions

15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.1.1 Research Programs/Design15.1.1.2 Market Size Estimation12.1.1.3 Market Breakdown and Data Triangulation15.1.2 Data Source15.1.2.1 Secondary Sources15.1.2.2 Primary Sources15.2 Disclaimer15.3 Author Details

Continued.

About Us:

Market Reports Worldis the Credible Source for Gaining the Market Reports that will Provide you with the Lead Your Business Needs. Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.

CONTACT US

Name: Ajay More

Email:[emailprotected]

Phone:US +1 424 253 0807 /UK +44 203 239 8187

Other Reports Here:

Neuroprosthetic System Market Industry Share, Size:2020 Market Research with Growth, Manufacturers, Segments and 2024 Forecasts Research

Folic Acid Market 2020 Size,Share Global Growth Analysis, Trends, Industry Analysis, Key Players and Forecast to 2026

Lithium Silicate Market Global Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand and Leading Players Updates by Forecast to 2026

Naltrexone HCL Market 2020 Size,Share Global Future Trend, Segmentation, Business Growth, Top Key Players Analysis Industry, Opportunities and Forecast to 2026

Magnetic Separators For Waste And Recycling Market 2020 Size,Share Global Forthcoming Developments, Industry Updates, Leading Players,Future Growth, Business Prospects and Future Investments by Forecast to 2025

Yeast and Yeast Extract Market 2020 Size,Share Global Competition Strategies, Statistics, Industry Trends, Revenue Analysis, Key Players, Regional Analysis by Forecast to 2024

Read more from the original source:
Prenatal and New-born Genetic Testing Market 2020 Size with Top Manufactures are Agilent Technologies, Inc.,Bio-Rad Laboratories, Inc.,Natera,...

Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries),…

New York, July 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" - https://www.reportlinker.com/p05930381/?utm_source=GNW

Product Type:Kits, Consumables, and Services Sample Type: Tumor Tissue, Blood, Saliva, Bone Marrow Technology: Next Generation Sequencing, Polymerase Chain Reaction,Immunohistochemistry, In-situ Hybridization, Microarray Techniques Oncology Genetic Testing: Breast, Colorectal,Prostate, Lung, Melanoma Cardiology Genetic Testing: Cardiomyopathy,Aortopathy, Arrythmia Neurology Genetic Testing: Epilepsy, Neurodegenerative Disorders, Neuromuscular Disorders Other Genetic Testing: Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Application Area: Academia and Research Centers, Clinical Diagnostics, Drug Discovery, Monitoring and Screening

Regional Segmentation North America U.S., Canada Europe Germany, France, Italy, U.K., Spain, Russia, Netherlands Asia-Pacific Japan, China, India, Australia, Singapore Latin America Brazil, Mexico Rest-of-the-World Kingdom of Saudi Arabia (K.S.A.), U.A.E., Palestine, Algeria

Cross Segmentation North America Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Europe Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Asia-Pacific - Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Latin America Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Rest-of-the-World Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing

Growth Drivers Rising Prevalence of Genetic Disorders Increasing Prevalence of Various Types of Cancer, Globally Increasing Research Funding in the Field of Genomics

Market Challenges Expensive Sequencing Procedures and Their Applications in Medical Treatments High Capital Requirement Hampering the Expansion of Global Reach Stringent Regulatory Standards

Market Opportunities Technological Advancements for Exome Sequencing Rise of Direct-to-Consumer (DTC) Testing Services Massive Scope for Adoption of NGS-Based in Emerging Nations

Key Companies ProfiledAgilent Technologies, Inc., Ambry Genetics, Beijing Genomics Institute (BGI), CENTOGENE AG, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Inc. Illumina, Inc. , Laboratory Corporation of America Holdings, Myriad Genetics, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.

Key Questions Answered in this Report: What are the possible long-term and short-term impacts of hereditary genetic testing on the human health continuum? What are the major market drivers, challenges, and opportunities in the hereditary genetic testing? What are the key development strategies which are being implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in the developed and developing regions for the global hereditary genetic testing market? How are service-based companies impacting the growth of the global hereditary genetic testing industry and further shaping up future trends? How each segment of the market is expected to grow during the forecast period from 2020 to 2030? Who are the leading players with significant offerings to the global hereditary genetic testing market? What is the expected market dominance for each of these leading players? Which companies are anticipated to be highly disruptive in the future, and why? What are the needs that are yet to be met by the global hereditary genetic testing market with respect to the application area? What are the dynamics of various application areas and countries are impacting the global hereditary genetic testing market? What are the new market opportunities of various technologies influencing the growth of the global hereditary genetic testing market?

Market OverviewThe hereditary genetic testing has grown significantly since the technology was first commercialized, but it is important to quantify that growth and describe future trends.The genome testing industry is proliferating, and its growth is expected to continue at its torrid pace.

However, there are significant challenges that may dampen future growth if not addressed.

Our healthcare experts have found hereditary genetic testing to be one of the most rapidly evolving technologies, and the global market for hereditary genetic testing is predicted to grow at a CAGR of 13.59% over the forecast period of 2020-2030.

The unmet clinical needs for better tools to predict, diagnose, treat, and monitor disease are acting as significant factors driving the growth of sequencing industry. Other factors driving the growth include the increased understanding of the molecular basis of disease, patient demand, industry investment, and regulations that allow marketing of tests without FDA approval.

Despite rapid advanced sequencing industry growth, there are several key issues that are needed to be addressed to facilitate future growth.The relatively high total costs of delivering sequencing test results compared with other technology platforms, and limited coverage by payers, are the key challenges to the growth of this industry.

Whole genome and exome sequencing remain relatively costly requiring initial equipment investment, specialized workforce requirements, and time-intensive variant interpretation.

Within the research report, the market is segmented on the basis of oncology genetic testing, cardiology genetic testing, neurology genetic testing, product, sample, application area, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive LandscapeThe exponential rise in the application of next generation sequencing on the global level has created a buzz among companies to invest in the products and services of whole genome and exome sequencing. Due to the diverse product portfolio and intense market penetration, whole genome and exome has been a pioneer in this field and been a significant competitor in this market.

On the basis of region, North America holds the largest share, due to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Latin America and the Asia-Pacific region are anticipated to grow at the fastest CAGR during the forecast period.

Countries Covered North America U.S. Canada Europe Germany France Italy U.K. Spain Russia Netherlands Rest-of-Europe Asia-Pacific China Japan India Australia Singapore Rest-of-APAC Latin America Brazil Mexico Rest-of-Latin America Rest-of-the-World (RoW)Read the full report: https://www.reportlinker.com/p05930381/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the original post here:
Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries),...

Pre-Pregnancy Genetic Testing Expected to Witness a Fast-paced Growth Over the Forecast Period 2016 2026 Bulletin Line – Bulletin Line

A new intelligence report Pre-Pregnancy Genetic Testing Market has been recently Added into Global Market Research collection of top-line market research reports. Global Pre-Pregnancy Genetic Testing Market report is a meticulous comprehensive analysis of this market that provides access to direct first-hand insights on the growth trail of market in near term and long term. On the basis of factual advice sourced from authentic industry pros and extensive main industry research, the report provides insights about the historical growth pattern of Pre-Pregnancy Genetic Testing Market and current market situation. It then provides short- and long-term market development projections.

Projections are purely based on the detailed analysis of key Market dynamics that are expected to influence Pre-Pregnancy Genetic Testing Market performance and their intensity of impacting market growth within the span of assessment period.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-1458

In addition to evaluation of dynamics, the report provides In-depth examination of key business trends that are expected to act more prominently in global Pre-Pregnancy Genetic Testing Market. The study also provides valued information about the present and upcoming growth opportunities in Pre-Pregnancy Genetic Testing Market the important players and new market entrants can capitalize on.

Competitive companies And manufacturers in global market

Key Players

Some of the key market players for genetic testing market are Sequenom Laboratories, Illumina, Inc, Natera, Inc, Ariosa Diagnostics, Inc, BGI Health, Natera and LifeCodexx.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes:

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

Asia Pacific (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-1458

Opportunity assessment Provided in the Pre-Pregnancy Genetic Testing Market report Is important concerning understanding the profitable regions of investment, which are the technical insights for major market players, suppliers, vendors, and other stakeholders in Pre-Pregnancy Genetic Testing Market.

In-depth global Pre-Pregnancy Genetic Testing Market taxonomy presented in this Report offers detailed insights about each of the market sections and their sub-segments, which are categorized based on par various parameters. An exhaustive regional evaluation of global Pre-Pregnancy Genetic Testing Market divides international market landscape into essential geographies.

Regional outlook and country-wise evaluation of Pre-Pregnancy Genetic Testing Market Allows for the evaluation of multi-faceted performance of market in all the crucial markets. This advice plans to provide a wider scope of report to readers and identify the most relevant profitable areas in global market place.

Key Regions and Countries Covered in Global Pre-Pregnancy Genetic Testing Market Report-

Taxonomy and geographical analysis of the international Pre-Pregnancy Genetic Testing Market empowers readers to spot profits in present chances and catch upcoming growth opportunities even until they approach the market location. The analysis given in report is only intended to unroll the economic, societal, regulatory and political scenarios of the marketplace specific to each area and country, which might help prospective market entrants in Pre-Pregnancy Genetic Testing Market landscape to comprehend the nitty-gritty of target market regions and invent their strategies accordingly.

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-1458

Major TOC Covered In this Report are:

Excerpt from:
Pre-Pregnancy Genetic Testing Expected to Witness a Fast-paced Growth Over the Forecast Period 2016 2026 Bulletin Line - Bulletin Line

Archives